PRAC Recommends Restrictions on Fluoroquinolone, Quinolones

Source: Medscape

The European Medicine Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has recommended restricting the use of systemic and inhaled fluoroquinolone and quinolone antibiotics following a safety review, according to a Medscape report.

“Very rarely, patients treated with fluoroquinolone or quinolone antibiotics have suffered long-lasting and disabling side effects, mainly involving muscles, tendons, and bones, and the nervous system,” the EMA said in a news release.

The PRAC also advised that some medicines, including all those that contain a quinolone antibiotic, be removed from the market.

Read the full article.

Recent Content